Navigation Links
Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
Date:5/21/2008

mmon malignancy found in women. Cervical cancer is caused by "high-risk" types of the human papillomavirus (HPV), which are sexually transmitted. It's estimated that 80 percent of women will get an HPV infection at some point in their lives. However, in most cases, the infection goes away or is suppressed by the body without causing problems. It is only infections that persist that can cause abnormal cells to form that may develop into cervical cancer if not detected and treated early. One report from the World Health Organization estimates that only about 5 percent of women had been screened for cervical disease in the previous five years, compared to 40-50 percent in the developed world.

About QIAGEN (http://www.qiagen.com)

QIAGEN NV, headquartered in the Netherlands, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue, and assays make these isolated molecules visible to facilitate such vital activities as biological research and detection of disease. QIAGEN has developed and markets more than 500 products as well as instruments that make their use more efficient and accurate. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide, including the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 2,600 people in over 30 locations worldwide.

Pam Rasmussen Dr. Thomas Theuringer

QIAGEN Gaithersburg QIAGEN GmbH

+1-240-686-7616 +49-
'/>"/>

SOURCE Qiagen N V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
2. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
3. Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone, Study of High-Risk Population Finds
4. Study Analyzed SYMBICORT(R) in Children with Persistent Asthma
5. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
7. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
8. Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
9. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
10. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
11. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015  The strongest driver of demand ... increasing elderly population, according to Kalorama Information. The ... the healthcare market research publisher, Global Orthopedic ... risk factors such as obesity is contributing to ... innovative product designs and the trend toward cost ...
(Date:3/4/2015)... DIEGO , March 4, 2015  Tandem Diabetes Care®, ... and manufacturer of the t:slim® and t:flex™ Insulin Pumps, today ... of 6,037,500 shares of common stock at a price to ... in full by the underwriters of their option to purchase ... in the offering were offered by Tandem. ...
(Date:3/4/2015)... PARK, Calif. , March 4, 2015 ... company in the emerging field of regenerative medicine, today ... Executive Officer, will ring The Opening Bell ® ... March 5, 2015. Asterias began trading as an NYSE ... "New York Stock Exchange is a trusted partner ...
Breaking Medicine Technology:Kalorama: Growing Elderly Population Drives Orthopedic Device Market 2Kalorama: Growing Elderly Population Drives Orthopedic Device Market 3Tandem Diabetes Care Announces Closing of Underwritten Public Offering of Common Stock 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 3
... (OTCQX: DATA), a technology and services company focused on global ... signing of a new client with the award of a ... in aneurysm repair. This six year, US-based study will ... for thoracic aortic aneurysms. , "DATATRAK is excited to work ...
... Healthcare Services, Inc. (NYSE: AHS ), the largest healthcare ... conference call to discuss third quarter results on Thursday, October ... expects to issue an earnings news release on Thursday, October ... p.m. Eastern Time. , A live webcast of the call ...
Cached Medicine Technology:DATATRAK Signs 6 Year Study with New Device Client 2DATATRAK Signs 6 Year Study with New Device Client 3AMN Healthcare Services to Host 2009 Third Quarter Earnings Conference Call on Thursday, October 29, 2009 2
(Date:3/4/2015)... The emergence of nanotechnology has ... past decade. The pharmaceutical world has witnessed advancements ... the form of liposomes and polymeric nanoparticles that ... safety and efficiency. In the area of ... upon the enhanced permeability and retention (EPR) effect ...
(Date:3/4/2015)... (PRWEB) March 05, 2015 The ... a value of $5,632.8 million by 2019, at ... of 2014 to 2019. , Browse through the ... analysis of industry trends and segments, with the ... , Phthalic Anhydride (PA) is a derivative ...
(Date:3/4/2015)... March 04, 2015 Dr. Christopher Asandra, ... Medical Center today lamented the FDA’s recent decision ... (TRT). He argued that FDA’s conclusions are not ... men who suffer from testosterone deficiency. , “The FDA ... on testosterone replacement therapy,” said Dr. Asandra. “There is ...
(Date:3/4/2015)... March 04, 2015 FDA’s New Inspection ... **FDAnews Webinar**, March 24, 2015 — 1:30 p.m. – ... generally know within four hours of an inspection whether ... is on their “good” list, they’ll merely ask for ... manufacturer is on the “bad” list, the manufacturer must ...
(Date:3/4/2015)... York, NY (PRWEB) March 04, 2015 ... creative, breakthrough marketing campaign called 'We Love Smokers' from ... cravings for tobacco. , "It’s important to establish ... be true to it. Our idea, 'We Love Smokers' ... leadership point of view. We created a bold tone ...
Breaking Medicine News(10 mins):Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 2Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 3Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 2Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 3Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 2Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 3
... to Iowa from Los Angeles; more ... shipments from Chicago planned, LOS ANGELES, ... Christian relief agency World Vision is dispatching an,initial truckload of emergency ... of affected families., "World Vision will be providing basic items ...
... complain that math homework won,t help them in real life, ... cancer. , In a recent study that combined math and ... (CML) may be cured of the disease with an optimally ... their own immune response. , In the June 20 edition ...
... to pulmonary arterial hypertension, study found , , THURSDAY, ... reduced clinical decline in patients with early-stage pulmonary ... is a progressive disease in which increased pulmonary ... the heart, eventually leading to heart failure and ...
... Pa., June 19 ADVERTISEMENT - The following,statement was ... Topaz &,Kessler, LLP:, Schiffrin Barroway Topaz & Kessler, ... In re Merck & Co. Inc. Securities, Derivative, &,ERISA ... Court for the,District of New Jersey. The Court recently ...
... Fix Competitive Bidding System for DMEPOS,Equipment, ALEXANDRIA, ... of the House Ways & Means Health Subcommittee, ... Reform,Act of 2008. Sens. Max Baucus (D-MT) and ... Senate Finance Committee, have introduced S.3144, the,companion bill. ...
... to Pennsylvania-Grown Tomatoes, HARRISBURG, Pa., June 19 ... been confirmed among Pennsylvania,residents, State Health Secretary Dr. ... to the current multi-state Salmonella outbreak,associated with tomatoes ... April., One case each has been identified ...
Cached Medicine News:Health News:World Vision Responding to Record Flooding in Midwest 2Health News:Math could help cure leukemia 2Health News:Math could help cure leukemia 3Health News:Drug Effective Against Heart-Lung Disorder 2Health News:Schiffrin Barroway Topaz & Kessler, LLP Announces Court Ruling Relating to Merck & Co. Inc.'s Employee Savings & Security Plan, the Merck & Co., Inc. Employee Stock Purchase & Savings Plan, and the Merck Puerto Rico Employee Savings & Security Plan 2Health News:Schiffrin Barroway Topaz & Kessler, LLP Announces Court Ruling Relating to Merck & Co. Inc.'s Employee Savings & Security Plan, the Merck & Co., Inc. Employee Stock Purchase & Savings Plan, and the Merck Puerto Rico Employee Savings & Security Plan 3Health News:NCPA Statement Endorsing H.R. 6252 and S.3144 2Health News:Pennsylvania Department of Health Confirms Fifth Salmonella Case Linked to National Outbreak 2
Data review and analysis is carried out with the Acquidata Uromac software already supplied with Acquidata Uromac Lab based urodynamics systems...
The Uromac Petite data processor, transducers and Powerbook® computer can be disassembled quickly and easily for travel to multiple sites, providing a very flexible and portable urodynamics syste...
... by Laborie, a leading producer ... credible tracings. ICS recognized Urodynamics ... parameters. Designed especially for the ... to be quick, efficient and ...
... offers ultimate flexibility by allowing you to ... and display. Wall-mount anywhere in the room. ... a laptop, touch screen tablet, industrial PC, ... this multi-function patient tower provides more power ...
Medicine Products: